News

Lens thickness and ciliary muscle are not affected by low-dose pilocarpine.

Benjamin P. Casella, OD, FAAO, shares perspectives on the most impactful glaucoma developments from the past year and the future role of interventional and personalized care.

Data estimates the prevalence of glaucoma currently is almost 50% higher than previously estimated and over 1.6 million individuals in the UK are estimated to have glaucoma by 2060.

Keeping a pulse on current developments has helped optometrists look to the future

The investigational new drug (IND) application from Complement Therapeutics for CTx001 was previously approved by the FDA in October 2025.

ODs are gearing up for anticipated advancements in specialty lens and lenses for myopia management and patients with astigmatism.

Kuzniar's OGSLS 2026 poster presentation provides a follow-up to previous fitting findings for the Zenlens Chroma HOA lens.

Key clinical trial data and PDUFA dates in early 2026 focus on treatments for dry eye, age-related macular degeneration, and rare eye diseases.

A total of 38 patients were included in the study. All underwent implantation of the PRIMAretinal prosthetic chip with the goal of restoring vision.

Jason Jedlicka, OD, FAAO, talks through a presentation he gave during last week's conference.

Previously, the EDOF technology was specifically limited to intraocular lenses.

Employers are obliged to provide employees with appropriate safety eyewear and face protection that conforms to the industry standard.

Chronic ocular diseases and ocular surface diseases alike now have new treatment options.

“Remarkable” results were reportedly obtained with hypotony with hydroxypropyl methylcellulose.

Susan Gromacki, OD, MS, FAAO, FSLS, details her presentation given at this year's conference.

Jamie Kuzniar, OD, FAAO, FSLS, details a poster presentation that served as a follow-up to results of previous fittings of Zenlens Chroma HOA (Bausch + Lomb).

Jason Jedlicka, OD, overviews his poster, “A Custom Wavefront-Guided Scleral Lens System For Higher Order Aberrations: Real-World Early Experience From a Retrospective Multicenter Case Review.”

New clinical data and trial updates closed out 2025.

A unique case study of HZO featuring Steve Silberberg, OD, DipABO, as the patient.

The lens was developed in collaboration with Brien Holden Vision Institute (BHVI).

Kramer, OD, FAAO, FSLS, presented alongside Kelsea Skidmore, OD, MS; Vivien Tse, OD; and Elaine Chen, OD, at this year's conference.

Investigators presented genomic, transcriptomic, histological and functional evidence that the Greenland shark retains an intact visual system well-adapted for life in dim light.

Utilize oral agents, diet, and glucose monitoring systems when acting to preserve vision.

Edward Choy, partner at Sho Eyeworks, shares success stories of private practices creating their own eyewear frame line.

Knowing what’s on the market for AMD and GA aids in preserving vision.

Evolutions in AI, myopia management, and individualized care are on ODs' minds for the new year.

The FDA issued a CRL for ONS-5010, citing the need for additional confirmatory efficacy evidence despite previous trials showing efficacy, according to the company.

Edward Choy, partner at Sho Eyeworks, advises practice owners on the fence of developing their own brand to dive in.